QRG Capital Management Inc. Invests $3.15 Million in Hims & Hers Health, Inc. (NYSE:HIMS)

QRG Capital Management Inc. acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 155,952 shares of the company’s stock, valued at approximately $3,149,000. QRG Capital Management Inc. owned about 0.07% of Hims & Hers Health as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of HIMS. Gunderson Capital Management Inc. bought a new position in Hims & Hers Health in the second quarter worth approximately $1,836,000. Cetera Advisors LLC bought a new stake in Hims & Hers Health during the first quarter valued at about $396,000. Farallon Capital Management LLC grew its holdings in Hims & Hers Health by 3,890.5% during the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after purchasing an additional 1,634,000 shares during the period. Virtu Financial LLC purchased a new stake in Hims & Hers Health in the first quarter worth about $638,000. Finally, Strategic Wealth Partners Ltd. bought a new position in shares of Hims & Hers Health in the first quarter worth about $839,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of HIMS traded up $0.11 during mid-day trading on Friday, hitting $15.96. 8,244,545 shares of the stock were exchanged, compared to its average volume of 7,900,966. The company has a market cap of $3.43 billion, a PE ratio of -1,596.00 and a beta of 1.08. Hims & Hers Health, Inc. has a 52-week low of $5.65 and a 52-week high of $25.74. The firm has a 50-day moving average of $21.12 and a two-hundred day moving average of $15.96.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The company had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. During the same quarter in the prior year, the firm earned ($0.03) earnings per share. Hims & Hers Health’s revenue was up 51.8% on a year-over-year basis. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.2 EPS for the current year.

Insider Activity

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $19.88, for a total transaction of $3,755,093.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $19.88, for a total transaction of $3,755,093.44. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Christiane Pendarvis sold 4,000 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $12.33, for a total value of $49,320.00. Following the transaction, the director now owns 11,210 shares in the company, valued at approximately $138,219.30. The disclosure for this sale can be found here. Insiders sold 980,907 shares of company stock valued at $19,445,689 in the last ninety days. Insiders own 17.71% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. TD Cowen increased their target price on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Citigroup downgraded shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and raised their price objective for the company from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Piper Sandler restated a “neutral” rating and set a $18.00 target price on shares of Hims & Hers Health in a research note on Tuesday. Truist Financial increased their price target on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Finally, Jefferies Financial Group raised their price target on Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, June 27th. Eight investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $20.00.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.